Table 4.
Adverse events occurring in ≥30% of patients in any treatment group
| Nab‐paclitaxel (n = 100) | Docetaxel (n = 100) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any grade | ≥Grade 3 | Any grade | ≥Grade 3 | |||||
| n | (%) | n | (%) | n | (%) | n | (%) | |
| Any adverse events | 100 | (100.0) | 88 | (88.0) | 100 | (100.0) | 99 | (99.0) |
| Hematologic toxicity | ||||||||
| Neutropenia | 97 | (97.0) | 78 | (78.0) | 99 | (99.0) | 98 | (98.0) |
| Leukopenia | 96 | (96.0) | 58 | (58.0) | 99 | (99.0) | 90 | (90.0) |
| Non‐hematotologic toxicity | ||||||||
| Alopecia | 95 | (95.0) | 0 | 91 | (91.0) | 0 | ||
| Peripheral sensory neuropthy | 88 | (88.0) | 22 | (22.0) | 69 | (69.0) | 5 | (5.0) |
| Rash | 61 | (61.0) | 1 | (1.0) | 50 | (50.0) | 0 | |
| Nail disorder | 57 | (57.0) | 0 | 57 | (57.0) | 0 | ||
| Anemia | 51 | (51.0) | 5 | (5.0) | 36 | (36.0) | 1 | (1.0) |
| Arthralgia | 47 | (47.0) | 1 | (1.0) | 40 | (40.0) | 0 | |
| Diarrhea | 44 | (44.0) | 0 | 48 | (48.0) | 2 | (2.0) | |
| Muscle pain | 44 | (44.0) | 1 | (1.0) | 46 | (46.0) | 0 | |
| Nausea | 43 | (43.0) | 1 | (1.0) | 44 | (44.0) | 0 | |
| Stomatitis | 42 | (42.0) | 1 | (1.0) | 34 | (34.0) | 0 | |
| Taste disturbance | 42 | (42.0) | 0 | 67 | (67.0) | 1 | (1.0) | |
| Edema | 40 | (40.0) | 3 | (3.0) | 51 | (51.0) | 4 | (4.0) |
| Malaise | 40 | (40.0) | 1 | (1.0) | 44 | (44.0) | 1 | (1.0) |
| Loss of appetite | 39 | (39.0) | 3 | (3.0) | 49 | (49.0) | 0 | |
| Nasopharyngitis | 38 | (38.0) | 0 | 36 | (36.0) | 0 | ||
| Fatigue | 33 | (33.0) | 1 | (1.0) | 31 | (31.0) | 0 | |
| Constipation | 25 | (25.0) | 1 | (1.0) | 30 | (30.0) | 0 | |
| Fever | 20 | (20.0) | 0 | 30 | (30.0) | 0 | ||
Analysis set: all treated patients.